Amphastar Pharmaceuticals (NASDAQ:AMPH) EVP Rong Zhou Sells 10,000 Shares of Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Rong Zhou sold 10,000 shares of the company’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $23.94, for a total transaction of $239,400.00. Following the sale, the executive vice president directly owned 169,203 shares of the company’s stock, valued at $4,050,719.82. The trade was a 5.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Rong Zhou also recently made the following trade(s):

• On Wednesday, September 2nd, Rong Zhou sold 3,187 shares of Amphastar Pharmaceuticals stock. The shares were sold at an average price of $23.63, for a total transaction of $75,308.81.

Amphastar Pharmaceuticals Stock Down 0.5%

AMPH stock opened at $23.82 on Friday. The company has a quick ratio of 1.71, a current ratio of 2.40 and a debt-to-equity ratio of 0.79. The business’s 50-day moving average price is $21.19 and its 200-day moving average price is $20.33. Amphastar Pharmaceuticals, Inc. has a twelve month low of $16.65 and a twelve month high of $29.52. The stock has a market cap of $1.01 billion, a P/E ratio of 14.09, a PEG ratio of 4.61 and a beta of 0.92.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.29. Amphastar Pharmaceuticals had a net margin of 10.76% and a return on equity of 14.98%. The company had revenue of $183.90 million for the quarter, compared to the consensus estimate of $179.92 million. On average, equities research analysts forecast that Amphastar Pharmaceuticals, Inc. will post 2.46 EPS for the current year.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Quantbot Technologies LP purchased a new stake in shares of Amphastar Pharmaceuticals during the second quarter valued at about $39,000. TD Private Client Wealth LLC raised its stake in shares of Amphastar Pharmaceuticals by 410.1% during the 4th quarter. TD Private Client Wealth LLC now owns 2,418 shares of the company’s stock worth $65,000 after acquiring an additional 1,944 shares in the last quarter. Hantz Financial Services Inc. lifted its position in Amphastar Pharmaceuticals by 43.6% during the fourth quarter. Hantz Financial Services Inc. now owns 4,484 shares of the company’s stock valued at $120,000 after acquiring an additional 1,362 shares during the last quarter. State of Wyoming purchased a new stake in Amphastar Pharmaceuticals during the second quarter valued at approximately $142,000. Finally, ProShare Advisors LLC boosted its stake in Amphastar Pharmaceuticals by 5.3% in the fourth quarter. ProShare Advisors LLC now owns 9,083 shares of the company’s stock valued at $243,000 after acquiring an additional 457 shares in the last quarter. Institutional investors own 65.09% of the company’s stock.

Analyst Upgrades and Downgrades

AMPH has been the subject of a number of recent research reports. Weiss Ratings reissued a “sell (d+)” rating on shares of Amphastar Pharmaceuticals in a report on Wednesday, July 8th. Bank of America reissued an “underperform” rating and issued a $20.00 price objective (down from $25.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, June 29th. Barclays raised their price objective on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the company an “equal weight” rating in a research note on Tuesday, August 18th. Piper Sandler dropped their price target on Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “neutral” rating on the stock in a research report on Friday, August 7th. Finally, Wall Street Zen downgraded Amphastar Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 12th. Six research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Reduce” and a consensus price target of $22.50.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a biopharmaceutical company that develops, manufactures and markets injectable, inhaled and intranasal products. The company focuses on complex and technically challenging medicines, including products for diabetes, emergency medicine, respiratory conditions and other specialty-care applications.

Its marketed products include glucagon for treating severe hypoglycemia, BAQSIMI nasal glucagon, Primatene MIST for temporary relief of mild intermittent asthma symptoms, naloxone products for opioid overdose emergencies, and enoxaparin sodium injection, an anticoagulant.